KBC Group’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$44K Hold
4,573
– – ﹤0.01% 1753
2026
Q2
$36K Hold
4,573
– – ﹤0.01% 1796
2026
Q1
$27K Buy
+4,573
New +$30.3K ﹤0.01% 1816

Other funds holding XERS

KBC Group's XERS Position: Q3 2026 in Review

KBC Group held its Xeris Biopharma Holdings (XERS) position steady in Q3 2026 at 4,573 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

KBC Group first reported a position in XERS in Q1 2026 and has held it in 3 quarters since. 210 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • KBC Group held 4,573 shares of Xeris Biopharma Holdings worth $44K as of Q3 2026.
  • KBC Group left its Xeris Biopharma Holdings share count unchanged in Q3 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1753 holding.
  • KBC Group first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 3 quarters since.
  • 210 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.